Avid Bioservices Inc (CDMO)

[jq1234]

Abraxane ph3 trial 2-yr survival rate was 9 vs 4% per published result in NEJM http://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369

You are being too generous on math being the ONLY issue in that post. Funny it was cited as example of good dd!

He got Abraxane pancreatic cancer trial patient population completely wrong. Patient population was METASTATIC pancreatic cancer, which by definition is stage IV. He somehow linked to a completely different Abraxane pancreatic trial instead, patient population became stage I and II?! Abraxane trial even didn't include locally advanced pancreatic cancer which by definition is stage III. Just follow the NCI link he provided, scroll down to stage IV pancreatic cancer, Abraxane trial result is cited under that section. Thus Abraxane pancreatic cancer trial population is very similar to Bavituximab pancreatic trial patient population, the difference was on the margins.